ABBV-525: A phase 1 trial of ABBV-525 in people with B-cell lymphomas

This trial is testing the treatment ABBV-525 in adults with B-cell lymphomas.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05618028

Trial aim and background  

The aim of this trial is to find out how safe, well tolerated and effective the medication ABBV-525 is in the treatment of B-cell lymphomas.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter 

Adults with B cell lymphomas may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

  • The Christie Hospital, Manchester
  • Leeds Teaching Hospitals NHS Trust, Leeds

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05618028

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.